LexaGene Holdings receives purchase order for a MiQLab system from Ethos Discovery

LexaGene Holdings Inc (CVE:LXG) (OTCQB:LXXGF) (FRA:5XS2), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced Tuesday that it has received a purchase order for a MiQLab system from Ethos Discovery. 

“In veterinary health, there are many unmet clinical diagnostic needs where LexaGene’s technology can be of great value,” said Dr Chand Khanna, president of  Ethos Discovery, in a statement.  

“In 2021, we will collaborate with LexaGene on expanding the MiQLab’s capabilities to pursue additional diagnostic innovation in areas that are important for Ethos. We are thrilled to have the first point-of-care molecular diagnostic instrument available to veterinary health professionals and look forward to bringing this technology to Ethos hospitals in the future.”

READ: LexaGene places MiQLab system in microbiology lab at University of Pennsylvania’s School of Veterinary Medicine

LexaGene’s MiQLab is designed for use inside veterinary hospitals, where it will be run by veterinarians and clinic staff. The automated system is easy to use and is currently equipped with LexaGene’s Bacterial and AMR Panel capable of screening samples for the seven most common bacterial pathogens and 13 anti-microbial resistance markers. 

Rapid, in-hospital identification of pathogens and whether they are resistant to common therapies is extremely useful for veterinarians in making evidence-based patient care decisions. LexaGene’s MiQLab tests samples using real-time PCR is widely regarded as a gold-standard chemistry for its sensitivity and specificity.

“Up until now, veterinarians have had limited options for infectious disease testing,” said LexaGene CEO Dr Jack Regan. “Generally, veterinarians send collected samples to reference laboratories and wait up to five days or more to receive the results. This slow turn-around time and delay in proper treatment can be frustrating to many veterinarians and potentially harmful to their patients.”

Regan added: “With the MiQLab, we are changing veterinary diagnostics. Veterinarians will now have the opportunity to adopt an automated, rapid, in-hospital, reference laboratory quality testing solution so they can deliver world-class care. We are gaining traction by steadily building momentum with MiQLab in the veterinary market and are looking forward to meeting the demand and fulfilling orders in 2021.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors